BHCM
RNAM

Brevan Howard Capital Management’s Avidity Biosciences RNAM Stock Holding History

Brevan Howard Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,873
Closed -$929K – 2438
2025
Q4 		$929K Sell
12,873
-2,104
-14% -$136K 0.01% 802
2025
Q3 		$653K Buy
+14,977
New +$605K ﹤0.01% 1146
2025
Q1 		– Sell
-32,712
Closed -$951K – 1412
2024
Q4 		$951K Buy
32,712
+26,984
+471% +$1.13M 0.01% 447
2024
Q3 		$263K Buy
+5,728
New +$249K ﹤0.01% 904
2024
Q1 		– Sell
-12,380
Closed -$112K – 1304
2023
Q4 		$112K Buy
+12,380
New +$82.8K ﹤0.01% 947

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Brevan Howard Capital Management's RNAM Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 12,873 shares — an estimated $929K sold.

Brevan Howard Capital Management first reported a position in RNAM in Q4 2023 and held it in 5 quarters. The position peaked at $951K in Q4 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 12,873 Avidity Biosciences shares in Q1 2026, an estimated $929K.
  • Brevan Howard Capital Management first reported a position in Avidity Biosciences in Q4 2023 and held it in 5 quarters.
  • Brevan Howard Capital Management's Avidity Biosciences position peaked at $951K in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.